Study Title

68Ga-AAZTA-093 PET/CT: First-in-human Study in Patients With Prostate Cancer

Study Details

Description:

68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with prostate cancer.

Sponsor:

First Affiliated Hospital of Fujian Medical University

Government Study Link:

NCT06437496 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468